RN7SL253P

Across TCGA pan-cancer cohorts, RN7SL253P RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RN7SL253P’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where RN7SL253P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RN7SL253P is over-expressed in tumor, although a few such as LUSC and COAD show the opposite, repressed pattern.

THCA, PRAD, and LUSC are the cancer types where RN7SL253P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RN7SL253P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Female	All	+0.196	<.001	5	view →
PRAD	All	All	+0.163	<.001	2	view →
LUSC	Male	All	−0.092	.005	2	view →
COAD	Female	II,III,IV	−0.052	.036	2	view →
LUAD	Male	All	+0.334	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

RN7SL253P–THCA

Open the THCA breakdown →